Ho-Youn Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ho-Youn Kim has a total of 187 co-authors. Here are the top co-authors by number of shared publications:
- Sung-Hwan Park
Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Republic of Korea
16 shared publications - Ji Hyeon Ju
Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
10 shared publications - Seung-Ki Kwok
Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
7 shared publications - Mi-La Cho
Lab of Translational ImmunoMedicine (LaTIM), Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul, Korea
6 shared publications - Kyung-Su Park
Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
5 shared publications So-Youn Min
Division of Rheumatology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390; and
5 shared publications
Latest Publications
- Open Access
- 28 June 2016
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 14 (1) , 1-11
Amelioration of autoimmune arthritis by adoptive transfer of Foxp3-expressing regulatory B cells is associated with the Treg/Th17 cell balance
Foxp3 is a key regulator of the development and function of regulatory T cells (Tregs), and its expression is thought to be T cell-restricted. We found that B cells in mice can express Foxp3 and B cells expressing Foxp3 may play a role in preventing the development of collagen-induced arthritis (CIA) in DBA/1J mice. Foxp3 expression was modulated in CD19+ B cells by transfection with shRNA or using an over-expression construct. In addition, Foxp3-transfected B cells were adoptively transferred to CIA mice. We found that LPS or anti-IgM stimulation induced Foxp3 expression in B cells. Foxp3-expressing B cells were found in the spleens of mice. Over-expression of Foxp3 conferred a contact-dependent suppressive ability on proliferation of responder T cells. Down-regulation of Foxp3 by shRNA caused a profound induction in proliferation of responder T cells. Adoptive transfer of Foxp3+CD19+ B cells attenuated the clinical symptoms of CIA significantly with concomitant suppression of IL-17 production and enhancement of Foxp3 expression in CD4+ T cells from splenocytes. Our data indicate that Foxp3 expression is not restricted to T cells. The expression of Foxp3 in B cells is critical for the immunoregulation of T cells and limits autoimmunity in a mouse model.
- 28 June 2016
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 14 (1) , 1-11
Open AccessAmelioration of autoimmune arthritis by adoptive transfer of Foxp3-expressing regulatory B cells is associated with the Treg/Th17 cell balance
Foxp3 is a key regulator of the development and function of regulatory T cells (Tregs), and its expression is thought to be T cell-restricted. We found that B cells in mice can express Foxp3 and B cells expressing Foxp3 may play a role in preventing the development of collagen-induced arthritis (CIA) in DBA/1J mice. Foxp3 expression was modulated in CD19+ B cells by transfection with shRNA or using an over-expression construct. In addition, Foxp3-transfected B cells were adoptively transferred to CIA mice. We found that LPS or anti-IgM stimulation induced Foxp3 expression in B cells. Foxp3-expressing B cells were found in the spleens of mice. Over-expression of Foxp3 conferred a contact-dependent suppressive ability on proliferation of responder T cells. Down-regulation of Foxp3 by shRNA caused a profound induction in proliferation of responder T cells. Adoptive transfer of Foxp3+CD19+ B cells attenuated the clinical symptoms of CIA significantly with concomitant suppression of IL-17 production and enhancement of Foxp3 expression in CD4+ T cells from splenocytes. Our data indicate that Foxp3 expression is not restricted to T cells. The expression of Foxp3 in B cells is critical for the immunoregulation of T cells and limits autoimmunity in a mouse model.
- Open Access
- 1 October 2015
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 195 (7) , 3001-3010
IL-12p40 Homodimer Ameliorates Experimental Autoimmune Arthritis
IL-23 is the key cytokine that induces the expansion of Th17 cells. It is composed of p19 and p40 subunits of IL-12. The p40 subunit binds competitively to the receptor of IL-23 and blocks its activity. Our aim was to assess the preventive and therapeutic effect of the IL-12p40 homodimer (p40)2 subunit in autoimmune arthritis animal models. In the current study, using IL-1R antagonist–knockout mice and a collagen-induced arthritis model, we investigated the suppressive effect of (p40)2 on inflammatory arthritis. We demonstrated that the recombinant adenovirus-expressing mouse (p40)2 model prevented the development of arthritis when given before the onset of arthritis. It also decreased the arthritis index and joint erosions in the mouse model if transferred after arthritis was established. (p40)2 inhibited the production of inflammatory cytokines and Ag-specific T cell proliferation. It also induced CD4+CD25+Foxp3 regulatory T (Treg) cells in vitro and in vivo, whereas the generation of retinoic acid receptor–related organ receptor γt and Th17 cells was suppressed. The induction of Treg cells and the suppression of Th17 cells were mediated via activated STAT5 and suppressed STAT3. Our data suggest that (p40)2 suppressed inflammatory arthritis successfully. This could be a useful therapeutic approach in autoimmune arthritis to regulate the Th17/Treg balance and IL-23 signaling.
- 1 October 2015
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 195 (7) , 3001-3010
Open AccessIL-12p40 Homodimer Ameliorates Experimental Autoimmune Arthritis
IL-23 is the key cytokine that induces the expansion of Th17 cells. It is composed of p19 and p40 subunits of IL-12. The p40 subunit binds competitively to the receptor of IL-23 and blocks its activity. Our aim was to assess the preventive and therapeutic effect of the IL-12p40 homodimer (p40)2 subunit in autoimmune arthritis animal models. In the current study, using IL-1R antagonist–knockout mice and a collagen-induced arthritis model, we investigated the suppressive effect of (p40)2 on inflammatory arthritis. We demonstrated that the recombinant adenovirus-expressing mouse (p40)2 model prevented the development of arthritis when given before the onset of arthritis. It also decreased the arthritis index and joint erosions in the mouse model if transferred after arthritis was established. (p40)2 inhibited the production of inflammatory cytokines and Ag-specific T cell proliferation. It also induced CD4+CD25+Foxp3 regulatory T (Treg) cells in vitro and in vivo, whereas the generation of retinoic acid receptor–related organ receptor γt and Th17 cells was suppressed. The induction of Treg cells and the suppression of Th17 cells were mediated via activated STAT5 and suppressed STAT3. Our data suggest that (p40)2 suppressed inflammatory arthritis successfully. This could be a useful therapeutic approach in autoimmune arthritis to regulate the Th17/Treg balance and IL-23 signaling.
- 15 June 2014
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 192 (12) , 5579-5585
The Lupus Susceptibility Locus Sle1 Facilitates the Peripheral Development and Selection of Anti-DNA B Cells through Impaired Receptor Editing
Systemic lupus erythematosus is characterized by the spontaneous production of IgG autoantibodies in patients and lupus-prone mice. In this study, we investigated the effect of the Sle1 lupus susceptibility locus on the peripheral development of 56R+ anti-DNA transgenic B cells by tracking 56R+ B cells in mice without (B6.56R) or with (B6.Sle1.56R) the Sle1 locus. Compared with B6.56R mice, B6.Sle1.56R mice exhibited increased class-switched IgG2a anti-DNA Abs in their serum, encoded by the transgene. Interestingly, within the spleen, Sle1 facilitated the development of these cells into clusters of IgG2a class-switched B cells juxtaposed to CD4+ T cells within extrafollicular sites. Through sequence analysis of B cell hybridomas, we also found that B cells from B6.Sle1.56R mice are inefficient at Ig H and L chain editing. Thus, the Ig H chains in Sle1.56R+ B cells are partnered more often with cationic L chains that facilitate DNA binding. Taken together, these findings indicate that the Sle1 lupus-susceptibility locus may facilitate the emergence of anti-DNA B cells by subduing BCR revision and possibly by shaping the extrafollicular development of effector B cells, although the precise molecular mechanisms await further study.
- 15 June 2014
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 192 (12) , 5579-5585
The Lupus Susceptibility Locus Sle1 Facilitates the Peripheral Development and Selection of Anti-DNA B Cells through Impaired Receptor Editing
Systemic lupus erythematosus is characterized by the spontaneous production of IgG autoantibodies in patients and lupus-prone mice. In this study, we investigated the effect of the Sle1 lupus susceptibility locus on the peripheral development of 56R+ anti-DNA transgenic B cells by tracking 56R+ B cells in mice without (B6.56R) or with (B6.Sle1.56R) the Sle1 locus. Compared with B6.56R mice, B6.Sle1.56R mice exhibited increased class-switched IgG2a anti-DNA Abs in their serum, encoded by the transgene. Interestingly, within the spleen, Sle1 facilitated the development of these cells into clusters of IgG2a class-switched B cells juxtaposed to CD4+ T cells within extrafollicular sites. Through sequence analysis of B cell hybridomas, we also found that B cells from B6.Sle1.56R mice are inefficient at Ig H and L chain editing. Thus, the Ig H chains in Sle1.56R+ B cells are partnered more often with cationic L chains that facilitate DNA binding. Taken together, these findings indicate that the Sle1 lupus-susceptibility locus may facilitate the emergence of anti-DNA B cells by subduing BCR revision and possibly by shaping the extrafollicular development of effector B cells, although the precise molecular mechanisms await further study.
- Open Access
- 4 February 2014
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 16 (1) , R41
Generation of disease-specific induced pluripotent stem cells from patients with rheumatoid arthritis and osteoarthritis
Introduction: Since the concept of reprogramming mature somatic cells to generate induced pluripotent stem cells (iPSCs) was demonstrated in 2006, iPSCs have become a potential substitute for embryonic stem cells (ESCs) given their pluripotency and “stemness” characteristics, which resemble those of ESCs. We investigated to reprogram fibroblast-like synoviocytes (FLSs) from patients with rheumatoid arthritis (RA) and osteoarthritis (OA) to generate iPSCs using a 4-in-1 lentiviral vector system. Methods: A 4-in-1 lentiviral vector containing Oct4, Sox2, Klf4, and c-Myc was transduced into RA and OA FLSs isolated from the synovia of two RA patients and two OA patients. Immunohistochemical staining and real-time PCR studies were performed to demonstrate the pluripotency of iPSCs. Chromosomal abnormalities were determined based on the karyotype. SCID-beige mice were injected with iPSCs and sacrificed to test for teratoma formation. Results: After 14 days of transduction using the 4-in-1 lentiviral vector, RA FLSs and OA FLSs were transformed into spherical shapes that resembled embryonic stem cell colonies. Colonies were picked and cultivated on matrigel plates to produce iPSC lines. Real-time PCR of RA and OA iPSCs detected positive markers of pluripotency. Immunohistochemical staining tests with Nanog, Oct4, Sox2, Tra-1-80, Tra-1-60, and SSEA-4 were also positive. Teratomas that comprised three compartments of ectoderm, mesoderm, and endoderm were formed at the injection sites of iPSCs. Established iPSCs were shown to be compatible by karyotyping. Finally, we confirmed that the patient-derived iPSCs were able to differentiate into osteoblast, which was shown by an osteoimage mineralization assay. Conclusion: FLSs derived from RA and OA could be cell resources for iPSC reprogramming. Disease- and patient-specific iPSCs have the potential to be applied in clinical settings as source materials for molecular diagnosis and regenerative therapy.
- 4 February 2014
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 16 (1) , R41
Open AccessGeneration of disease-specific induced pluripotent stem cells from patients with rheumatoid arthritis and osteoarthritis
Introduction: Since the concept of reprogramming mature somatic cells to generate induced pluripotent stem cells (iPSCs) was demonstrated in 2006, iPSCs have become a potential substitute for embryonic stem cells (ESCs) given their pluripotency and “stemness” characteristics, which resemble those of ESCs. We investigated to reprogram fibroblast-like synoviocytes (FLSs) from patients with rheumatoid arthritis (RA) and osteoarthritis (OA) to generate iPSCs using a 4-in-1 lentiviral vector system. Methods: A 4-in-1 lentiviral vector containing Oct4, Sox2, Klf4, and c-Myc was transduced into RA and OA FLSs isolated from the synovia of two RA patients and two OA patients. Immunohistochemical staining and real-time PCR studies were performed to demonstrate the pluripotency of iPSCs. Chromosomal abnormalities were determined based on the karyotype. SCID-beige mice were injected with iPSCs and sacrificed to test for teratoma formation. Results: After 14 days of transduction using the 4-in-1 lentiviral vector, RA FLSs and OA FLSs were transformed into spherical shapes that resembled embryonic stem cell colonies. Colonies were picked and cultivated on matrigel plates to produce iPSC lines. Real-time PCR of RA and OA iPSCs detected positive markers of pluripotency. Immunohistochemical staining tests with Nanog, Oct4, Sox2, Tra-1-80, Tra-1-60, and SSEA-4 were also positive. Teratomas that comprised three compartments of ectoderm, mesoderm, and endoderm were formed at the injection sites of iPSCs. Established iPSCs were shown to be compatible by karyotyping. Finally, we confirmed that the patient-derived iPSCs were able to differentiate into osteoblast, which was shown by an osteoimage mineralization assay. Conclusion: FLSs derived from RA and OA could be cell resources for iPSC reprogramming. Disease- and patient-specific iPSCs have the potential to be applied in clinical settings as source materials for molecular diagnosis and regenerative therapy.
- 16 July 2013
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 17 (1) , 125-126
Medial tibial stress syndrome progressing to tibial fracture in rheumatoid arthritis
- 16 July 2013
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 17 (1) , 125-126
Medial tibial stress syndrome progressing to tibial fracture in rheumatoid arthritis
- 27 February 2013
- Published by Springer Nature in Rheumatology International
- Vol. 33 (8) , 2135-2140
Shared epitope and radiologic progression are less prominent in elderly onset RA than young onset RA
The aim of this study was to determine the influence of HLA-DRB1 and HLA-DQB1 genes on the disease susceptibility and the disease severity in elderly onset rheumatoid arthritis (EORA) compared with young onset rheumatoid arthritis (YORA) in Korean patients. Genetic analysis of HLA-DRB1 and HLA-DQB1 alleles was performed in three groups. Group 1 included 63 patients who were diagnosed with (rheumatoid arthritis) RA after the age of 60 (EORA). Group 2 consisted of 109 patients who were diagnosed with RA before the age of 60 (YORA). Group 3 involved 133 normal controls. The shared-epitope-coding alleles included the members of the HLA-DRB1*04 allele group (*0401, *0404, *0405, *0408, *0410), HLA-DRB1*01 allele group (*0101,*0102), HLA-DRB1*1001, and HLA-DRB1*1402. The disease severity was assessed by the modified total sharp score (mTSS). The shared-epitope-coding alleles were more frequently observed in the RA patients than in the normal controls. The shared-epitope-coding alleles were less frequently found in EORA group than YORA group (31/63 (49.2 %) in group 1, 72/109 (66.1 %) in group 2, 45/133 (33.8 %) group 3, p = 0.02). Although the mTSS of the group 1 was higher than group 2 at symptom onset, the overall mean mTSS of the group 1 was lower than that of group 2 (26.8 vs. 57.5, p < 0.05). HLA-DQ*04 showed the higher frequency in the patients group than in normal controls (p < 0.001). And HLA-DQ*04 was less commonly found in the patients with EORA than YORA (p < 0.05). The influence of shared epitope and HLA-DQ*04 alleles may be less significant on disease susceptibility in EORA. The presence of shared-epitope-coding alleles did not appear to influence on disease severity in EORA patients as well as in YORA patients. Radiologic deterioration in EORA group was less severe than in YORA group. The presence of shared epitope and radiologic progression are less prominent in EORA patients than YORA patients.
- 27 February 2013
- Published by Springer Nature in Rheumatology International
- Vol. 33 (8) , 2135-2140
Shared epitope and radiologic progression are less prominent in elderly onset RA than young onset RA
The aim of this study was to determine the influence of HLA-DRB1 and HLA-DQB1 genes on the disease susceptibility and the disease severity in elderly onset rheumatoid arthritis (EORA) compared with young onset rheumatoid arthritis (YORA) in Korean patients. Genetic analysis of HLA-DRB1 and HLA-DQB1 alleles was performed in three groups. Group 1 included 63 patients who were diagnosed with (rheumatoid arthritis) RA after the age of 60 (EORA). Group 2 consisted of 109 patients who were diagnosed with RA before the age of 60 (YORA). Group 3 involved 133 normal controls. The shared-epitope-coding alleles included the members of the HLA-DRB1*04 allele group (*0401, *0404, *0405, *0408, *0410), HLA-DRB1*01 allele group (*0101,*0102), HLA-DRB1*1001, and HLA-DRB1*1402. The disease severity was assessed by the modified total sharp score (mTSS). The shared-epitope-coding alleles were more frequently observed in the RA patients than in the normal controls. The shared-epitope-coding alleles were less frequently found in EORA group than YORA group (31/63 (49.2 %) in group 1, 72/109 (66.1 %) in group 2, 45/133 (33.8 %) group 3, p = 0.02). Although the mTSS of the group 1 was higher than group 2 at symptom onset, the overall mean mTSS of the group 1 was lower than that of group 2 (26.8 vs. 57.5, p < 0.05). HLA-DQ*04 showed the higher frequency in the patients group than in normal controls (p < 0.001). And HLA-DQ*04 was less commonly found in the patients with EORA than YORA (p < 0.05). The influence of shared epitope and HLA-DQ*04 alleles may be less significant on disease susceptibility in EORA. The presence of shared-epitope-coding alleles did not appear to influence on disease severity in EORA patients as well as in YORA patients. Radiologic deterioration in EORA group was less severe than in YORA group. The presence of shared epitope and radiologic progression are less prominent in EORA patients than YORA patients.
- 1 January 2013
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 20 (6) , 378-380
Simultaneous Presentation of Ocular Sarcoidosis and Early Axial Spondyloarthritis in a Young Woman
Lee JH, et al. J Rheum Dis. 2013 Dec;20(6):378-380. https://doi.org/10.4078/jrd.2013.20.6.378
- 1 January 2013
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 20 (6) , 378-380
Simultaneous Presentation of Ocular Sarcoidosis and Early Axial Spondyloarthritis in a Young Woman
Lee JH, et al. J Rheum Dis. 2013 Dec;20(6):378-380. https://doi.org/10.4078/jrd.2013.20.6.378
- Open Access
- 1 January 2013
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 20 (3) , 140-148
Epigenetic Modification in Systemic Rheumatic Diseases
Lee J, et al. J Rheum Dis. 2013 Jun;20(3):140-148. http://dx.doi.org/10.4078/jrd.2013.20.3.140
- 1 January 2013
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 20 (3) , 140-148
Open AccessEpigenetic Modification in Systemic Rheumatic Diseases
Lee J, et al. J Rheum Dis. 2013 Jun;20(3):140-148. http://dx.doi.org/10.4078/jrd.2013.20.3.140
- Open Access
- 28 December 2012
- Published by Wiley in Arthritis & Rheumatism
- Vol. 65 (4) , 949-959
p53 Controls Autoimmune Arthritis via STAT‐Mediated Regulation of the Th17 Cell/Treg Cell Balance in Mice
Objective: To investigate the connection between p53 and interleukin‐17–producing Th17 cell/Treg cell balance in rheumatoid arthritis (RA).Methods: Th17 cell and Treg cell frequencies were analyzed by flow cytometry, and cytokine levels in the supernatant were determined using enzyme‐linked immunosorbent assays. The expression of transcription factors was analyzed by immunostaining and Western blotting, and the interactions between p53 and STAT‐3 or STAT‐5 were determined by immunoprecipitation–Western blot analysis. A p53 agonist was administered in the collagen‐induced arthritis (CIA) model, and the effects in vivo were determined.Results: CD4+ T cells from p53–/– mice decreased the activity of STAT‐5, lowered the level of phosphorylated STAT‐5, and compromised Treg cell differentiation. The protein p53 bound STAT‐5 directly, and this interaction was enhanced with increasing p53 activity. Under inflammatory conditions, p53 suppressed Th17 cell differentiation and skewed T cells toward Treg cell differentiation through the activation of STAT‐5 signaling cascades. In mice with CIA, injection of a p53 overexpression vector or an antagonist of Mdm2 had the effect of controlling arthritis development in vivo. The regulatory effect of p53 was recapitulated in the cells of RA patients, with more pronounced suppression due to the repressed status of p53 in RA.Conclusion: We demonstrated a link between p53‐mediated and STAT‐mediated regulation of Th17 cells/Treg cells in RA. Our results suggest that factors involved in this pathway might constitute novel therapeutic targets for the treatment of RA.
- 28 December 2012
- Published by Wiley in Arthritis & Rheumatism
- Vol. 65 (4) , 949-959
Open Accessp53 Controls Autoimmune Arthritis via STAT‐Mediated Regulation of the Th17 Cell/Treg Cell Balance in Mice
Objective: To investigate the connection between p53 and interleukin‐17–producing Th17 cell/Treg cell balance in rheumatoid arthritis (RA).Methods: Th17 cell and Treg cell frequencies were analyzed by flow cytometry, and cytokine levels in the supernatant were determined using enzyme‐linked immunosorbent assays. The expression of transcription factors was analyzed by immunostaining and Western blotting, and the interactions between p53 and STAT‐3 or STAT‐5 were determined by immunoprecipitation–Western blot analysis. A p53 agonist was administered in the collagen‐induced arthritis (CIA) model, and the effects in vivo were determined.Results: CD4+ T cells from p53–/– mice decreased the activity of STAT‐5, lowered the level of phosphorylated STAT‐5, and compromised Treg cell differentiation. The protein p53 bound STAT‐5 directly, and this interaction was enhanced with increasing p53 activity. Under inflammatory conditions, p53 suppressed Th17 cell differentiation and skewed T cells toward Treg cell differentiation through the activation of STAT‐5 signaling cascades. In mice with CIA, injection of a p53 overexpression vector or an antagonist of Mdm2 had the effect of controlling arthritis development in vivo. The regulatory effect of p53 was recapitulated in the cells of RA patients, with more pronounced suppression due to the repressed status of p53 in RA.Conclusion: We demonstrated a link between p53‐mediated and STAT‐mediated regulation of Th17 cells/Treg cells in RA. Our results suggest that factors involved in this pathway might constitute novel therapeutic targets for the treatment of RA.
- Open Access
- 20 November 2012
- Published by Wiley in Immunology
- Vol. 137 (4) , 305-316
Interleukin‐2/anti‐interleukin‐2 monoclonal antibody immune complex suppresses collagen‐induced arthritis in mice by fortifying interleukin‐2/STAT5 signalling pathways
Summary: In this study, we investigated the effects of administration of interleukin‐2 (IL‐2)/JES6‐1 (anti‐IL‐2 monoclonal antibody) immune complexes on the expansion and activation of regulatory T (Treg) cells, the down‐regulation of T helper type 17 (Th17) cells, and the control of the severity of collagen‐induced arthritis (CIA). Wild‐type and CIA‐induced wild‐type mice were injected intraperitoneally (i.p.) with IL‐2 or IL‐2/JES6‐1 complex three times at 2‐day intervals. Treg cell surface markers were analysed by flow cytometry. After injecting IL‐2 or IL‐2/JES6‐1, the time kinetics of IL‐2 signalling molecules was examined by FACS and Western blotting. Concentrations of IL‐17 and IL‐10 were measured by ELISA. Injection of IL‐2/JES6‐1 increased the proportion of Foxp3+ Treg cells among splenic CD4+ T cells, which reached the highest level on day 4 after injection. Up‐regulation of CTLA4, GITR and glycoprotein‐A repetitions predominant (GARP) was observed. Activation of p‐signal transducer and activator of transcription 5 (STAT5) was apparent within 3 hr after injection of IL‐2/JES6‐1 complexes. Expression of IL‐2 signalling molecules, including p‐AKT and p‐p38/mitogen‐activated protein kinase, was also higher in splenocytes treated with IL‐2/JES6‐1 complexes. Injection of IL‐2/JES6‐1 complexes suppressed the induction of CIA and the production of IL‐17 and inflammatory responses while increasing the level of IL‐10 in the spleen. The expansion of Treg cells (via STAT5) and the concomitant increase in IL‐2 signalling pathways by IL‐2/JES6‐1 complexes suggests their potential use as a novel therapeutic agent for the treatment of autoimmune arthritis.
- 20 November 2012
- Published by Wiley in Immunology
- Vol. 137 (4) , 305-316
Open AccessInterleukin‐2/anti‐interleukin‐2 monoclonal antibody immune complex suppresses collagen‐induced arthritis in mice by fortifying interleukin‐2/STAT5 signalling pathways
Summary: In this study, we investigated the effects of administration of interleukin‐2 (IL‐2)/JES6‐1 (anti‐IL‐2 monoclonal antibody) immune complexes on the expansion and activation of regulatory T (Treg) cells, the down‐regulation of T helper type 17 (Th17) cells, and the control of the severity of collagen‐induced arthritis (CIA). Wild‐type and CIA‐induced wild‐type mice were injected intraperitoneally (i.p.) with IL‐2 or IL‐2/JES6‐1 complex three times at 2‐day intervals. Treg cell surface markers were analysed by flow cytometry. After injecting IL‐2 or IL‐2/JES6‐1, the time kinetics of IL‐2 signalling molecules was examined by FACS and Western blotting. Concentrations of IL‐17 and IL‐10 were measured by ELISA. Injection of IL‐2/JES6‐1 increased the proportion of Foxp3+ Treg cells among splenic CD4+ T cells, which reached the highest level on day 4 after injection. Up‐regulation of CTLA4, GITR and glycoprotein‐A repetitions predominant (GARP) was observed. Activation of p‐signal transducer and activator of transcription 5 (STAT5) was apparent within 3 hr after injection of IL‐2/JES6‐1 complexes. Expression of IL‐2 signalling molecules, including p‐AKT and p‐p38/mitogen‐activated protein kinase, was also higher in splenocytes treated with IL‐2/JES6‐1 complexes. Injection of IL‐2/JES6‐1 complexes suppressed the induction of CIA and the production of IL‐17 and inflammatory responses while increasing the level of IL‐10 in the spleen. The expansion of Treg cells (via STAT5) and the concomitant increase in IL‐2 signalling pathways by IL‐2/JES6‐1 complexes suggests their potential use as a novel therapeutic agent for the treatment of autoimmune arthritis.